Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455–456 synergistically enhances antibody evasion and ACE2 binding
Fanchong Jian,Leilei Feng,Sijie Yang,Yuanling Yu,Lei Wang,Weiliang Song,Ayijiang Yisimayi,Xiaosu Chen,Yanli Xu,Peng Wang,Lingling Yu,Jing Wang,Lu Liu,Xiao Niu,Jing Wang,Tianhe Xiao,Ran An,Yao Wang,Qingqing Gu,Fei Shao,Ronghua Jin,Zhongyang Shen,Youchun Wang,Xiangxi Wang,Yunlong Cao
DOI: https://doi.org/10.1371/journal.ppat.1011868
IF: 7.464
2023-12-21
PLoS Pathogens
Abstract:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) XBB lineages have achieved dominance worldwide and keep on evolving. Convergent evolution of XBB lineages on the receptor-binding domain (RBD) L455F and F456L is observed, resulting in variants with substantial growth advantages, such as EG.5, FL.1.5.1, XBB.1.5.70, and HK.3. Here, we show that neutralizing antibody (NAb) evasion drives the convergent evolution of F456L, while the epistatic shift caused by F456L enables the subsequent convergence of L455F through ACE2 binding enhancement and further immune evasion. L455F and F456L evade RBD-targeting Class 1 public NAbs, reducing the neutralization efficacy of XBB breakthrough infection (BTI) and reinfection convalescent plasma. Importantly, L455F single substitution significantly dampens receptor binding; however, the combination of L455F and F456L forms an adjacent residue flipping, which leads to enhanced NAbs resistance and ACE2 binding affinity. The perturbed receptor-binding mode leads to the exceptional ACE2 binding and NAb evasion, as revealed by structural analyses. Our results indicate the evolution flexibility contributed by epistasis cannot be underestimated, and the evolution potential of SARS-CoV-2 RBD remains high. The continuous evolution of SARS-CoV-2 presents a challenge to global public health and the development of vaccines and treatments against COVID-19. Recently, an adjacent residue alteration, L455F+F456L, also known as "FLip", on the receptor-binding domain of the virus, which has been identified in multiple strains of the virus, alters how the virus interacts with human cells and immune response. We show that the combination of these mutations synergistically increases the virus's ability to bind to ACE2, the primary receptor on cell surfaces, enabling it to specifically escape a public type of neutralizing antibodies elicited by vaccination and infection, and the molecular mechanisms are explained by structural analyses. The enhancement of receptor binding increases the potential of the virus to further accumulate immune evasive mutations. These findings broaden our understanding of SARS-CoV-2 evolution and highlight the importance of paying attention to these ongoing antigenic drifts in the virus as we continue to develop and evaluate current antibody therapeutics and vaccines.
microbiology,virology,parasitology